JAK2 and colorectal carcinoma: To this end, two CRC cancer cell lines, DLD-1 and HCT-116, were pre-treated with pacritinib or HO-3867 which are extensively investigated clinical or pre-clinical inhibitors targeting JAK2 and STAT3 respectively and subsequently co-cultured with conditioned medium from CAFs.